Sanofi touts promising Ph3 results for blockbuster diabetes program

Sanofi clearly impressed analysts with a new round of promising Phase III results on lixisenatide, its GLP-1 drug for diabetes. Sticking with the headline results for now, investigators reported that the treatment tied with basal insulin significantly lowered blood sugar levels as well as the weight of Type 2 diabetes patients. And that outcome will help set up the diabetes treatment as a potential blockbuster addition to its lineup of late-stage therapeutics.

Sanofi in-licensed lixisenatide from Zealand Pharma and would clearly like to pair it with Lantus, its insulin product which garnered some €3.5 billion last year. And Jefferies analysts cheered on the data regarding weight loss, which they believe will help ensure the treatment's "blockbuster success."

"These positive efficacy and safety results are another important milestone in the GetGoal clinical trial program and show the potential value of adding Lyxumia (lixisenatide) to basal insulin to improve glycemic control," said Pierre Chancel, Senior Vice President, Global Diabetes Division at Sanofi. "The findings from this and previous studies reinforce a continuing positive trend demonstrating the potential of lixisenatide to improve the lives of people with type 2 diabetes."

GetGoal-L is one of nine studies in the GetGoal Phase III clinical program, and the second trial to investigate the benefits of lixisenatide 20μg once-daily combined with basal insulin.

- here's the Sanofi release
- read the story from Reuters

Related Articles:
Sanofi's lixisenatide aces Phase III
Sanofi GLP-1 diabetes drug edges Byetta in Phase III study
Sanofi's GLP-1 drug hits promising marks in PhIII diabetes trial

Suggested Articles

Combining inhibitors of KRAS-G12C, mTOR and IGF1R can significantly shrink lung tumors in mice and human cancer cells, a study found.

X4 Pharmaceuticals has a new R&D chief: Renato Skerlj, who founded the company alongside CEO Paula Ragan and biotech luminary Henri Termeer.

Henlius Biotech missed the $477 million goal it set for its IPO, but still made the top five biopharma IPOs this year with its $410 million listing.